Clinical Trial

Phase I Clinical Study of LNF2105 in Patients With Advanced Solid Tumors

Name: Phase I Clinical Study of LNF2105 in Patients With Advanced Solid Tumors — clinical trial record (NCT07661797)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

This study is a Phase I clinical trial evaluating the safety, tolerability, pharmacokinetic characteristics, and preliminary antitumor efficacy of LNF2105 in patients with advanced solid tumors.

Trial Details

NCT Number	NCT07661797
Lead Sponsor	Shandong New Time Pharmaceutical Co., LTD
Conditions	Patients With Advanced Solid Tumors
Enrollment	294 participants
Start Date	2026-06
Primary Completion	2028-06 (estimated)
Study Completion	2028-08 (estimated)
Updated on ClinicalTrials.gov	2026-06-22